EUVIMEDEUVIMED entdecken
Crossref

Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis

Haiyang Li, Zhaohui Ruan, Yanan Jia, Yuan Zhang, Lingwa Wang, Yifan Yang, Ru Wang, Jugao Fang iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Haiyang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Nivolumab, Angiogenesis Inhibitors, Pharmacovigilance, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Capital Health Research and Development of Special Fund, National Natural Science Foundation of China, Beijing Medical Award Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Immune checkpoint inhibitors, such as nivolumab, combined with small molecule antiangiogenic receptor tyrosine kinase inhibitors (TKIs), present a promising strategy for future immunotherapy. However, combination therapy can lead to specific adverse drug reactions (ADRs) in various clinical settings. Current research on the ADRs associated with combination therapy is limited. Our study aims to assess the safety of combination therapy.

Methods

We extracted ADR reports on combination therapy from the Food and Drug Administration (FDA) Adverse Event Reporting System database, covering the period from the first quarter of 2012 to the third quarter of 2023, and conducted a large‐scale retrospective study. We evaluated ADR risk signals using the reporting odds ratio (ROR) and calculated the Ro/e ratio to compare the differences in the risk of fatal ADRs among various tumour types.

Results

We comprehensively reported the occurrence of ADRs in pan‐cancer patients undergoing combination therapy. The combination therapy significantly increased the risk of sensitive skin (ROR: 231.43, 95% CI: 55.01–973.72, P < .05), metastatic renal cell carcinoma (ROR: 220.71, 95% CI: 28.99–1695.41, P < .05) and renal cell carcinoma (ROR: 188.22, 95% CI: 44.24–800.85, P < .05). We also compared the differences in ADRs resulting from different small molecule drug combinations, as well as the differences in ADRs among patients with different types of tumours under combination therapy. Furthermore, we analysed the characteristics of patients prone to experiencing fatal ADRs.

Conclusion

These results can help enhance understanding of the ADRs commonly associated with combination therapy and assist oncologists in formulating screening protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabAngiogenesis InhibitorsPharmacovigilanceAdverse Drug Reaction Reporting SystemsHumansRetrospective StudiesMaleFemaleMiddle AgedUnited StatesAgedImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsDatabases, FactualAdultUnited States Food and Drug AdministrationProtein Kinase Inhibitors

Stichwörter der Autor:innen

FAERSadverse drug reactionsnivolumabretrospective studysmall molecule antiangiogenic drugs

Substanzen

NivolumabAngiogenesis InhibitorsImmune Checkpoint InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Changping Laboratory, Beijing, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
  • Zhanggongshan Communist Labour University, Shangrao, China.

ORCID-Profile: Jugao Fang

Förderung

  • Capital Health Research and Development of Special Fund
  • National Natural Science Foundation of China
  • Beijing Medical Award Foundation
  • Beijing Municipal Administration of Hospitals Incubating Program

Zitieren

APA

Li, H., Ruan, Z., Jia, Y., Zhang, Y., Wang, L., Yang, Y., Wang, R., & Fang, J. (2025). Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16242

Vancouver

Li H, Ruan Z, Jia Y, Zhang Y, Wang L, Yang Y, et al. Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16242

BibTeX
@article{Li2025,
  author = {Li, Haiyang and Ruan, Zhaohui and Jia, Yanan and Zhang, Yuan and Wang, Lingwa and Yang, Yifan and Wang, Ru and Fang, Jugao},
  title = {Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16242}
}
Kostenlos starten →